Quarterly report pursuant to Section 13 or 15(d)


3 Months Ended
Mar. 31, 2018
Business Combinations [Abstract]  
Business Acquisition, Pro Forma Information

The following unaudited pro forma consolidated results of operations have been prepared as if the acquisition of Beijing GenExosome had occurred as of the beginning of the following period:


    Three Months Ended March 31, 2017  
Net revenues   $ 66,286  
Net loss   $ (1,056,378 )
Net loss attributable to Avalon GloboCare Corp.   $ (1,053,082 )
Net loss per share   $ (0.02 )